

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)
Endocrinologic and Metabolic Drugs Advisory Committee Meeting

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31, the Great Room
White Oak Conference Center (Rm. 1503), Silver Spring, MD
December 11, 2013

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Karen Abraham-Burrell, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS
(Voting)**

Erica H. Brittain, PhD

Mathematical Statistician
Biostatistics Research Branch
National Institute of Allergy and Infectious
Diseases (NIAID)
National Institutes of Health (NIH)
Bethesda, Maryland

Ed J. Hendricks, MD

Medical Director
Center for Weight Management
Roseville, California

Edward W. Gregg, PhD

Chief, Epidemiology and Statistics Branch
Division of Diabetes Translation
Centers for Disease Control and Prevention
Atlanta, Georgia

Robert J. Smith, MD

(Acting Chairperson)
Professor of Medicine (Endocrinology)
Alpert Medical School of Brown University
Ocean State Research Institute
Providence Veterans Administration Medical
Center
Providence, Rhode Island

Diana Hallare, MPH

(Consumer Representative)
Visalia, California

Charles A. Stanley, MD

Professor of Pediatrics
University of Pennsylvania Perelman School of
Medicine
Division of Endocrinology & Diabetes
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)
Endocrinologic and Metabolic Drugs Advisory Committee Meeting

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31, the Great Room
White Oak Conference Center (Rm. 1503), Silver Spring, MD
December 11, 2013

DRAFT MEETING ROSTER (cont.)

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER
(Non-Voting)**

Mads F. Rasmussen, MD, PhD

(Industry Representative)

Project Vice President
GLP-1 and Obesity – Global Development
Novo Nordisk A/S
Denmark

TEMPORARY MEMBERS (Voting)

Joel E. Lavine, MD, PhD

Professor of Pediatrics
Columbia University
Chief, Gastroenterology, Hepatology and
Nutrition
Morgan Stanley Children's Hospital of New
York
New York, New York

John J. O'Shea, MD

Director, Intramural Research Program
National Institute of Arthritis and
Musculoskeletal and Skin Diseases, NIH
Bethesda, Maryland

Miriam Vos, MD, MSPH

Associate Professor of Pediatrics
Division of Pediatric Gastroenterology,
Hepatology and Nutrition
Emory University School of Medicine
Research Director, Health4Life Program
Children's Healthcare of Atlanta
Atlanta, Georgia

Dennis R. Ownby, MD

Section Chief of Allergy & Immunology
Professor of Pediatrics
Georgia Regents University
Augusta, Georgia

Bruce M. Smackey, PhD

(Patient Representative)
Bethlehem, Pennsylvania

Wyndham Wilson, MD

Senior Investigator and
Deputy Branch Chief
Lymphoid Malignancy Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)
Endocrinologic and Metabolic Drugs Advisory Committee Meeting

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
FDA White Oak Campus, Building 31, the Great Room
White Oak Conference Center (Rm. 1503), Silver Spring, MD
December 11, 2013

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Mary H. Parks, MD

Deputy Director
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

Eric Colman, MD

Deputy Director
Division of Metabolism and Endocrinology
Products (DMEP)
ODE-II, OND, CDER, FDA

James P. Smith, MD, MS

Clinical Team Leader
DMEP, ODE-II, OND, CDER, FDA

Julie K. Golden, MD

Medical Officer
DMEP, ODE-II, OND, CDER, FDA

Suzanne Berkman Robottom, PharmD

Division of Risk Management
Office of Medication Error Prevention and Risk
Management
Office of Surveillance and Epidemiology
CDER, FDA